Abstract:Background: Cancer targeting nanoprobes with precisely designed physicochemical properties may show enhanced pharmacological targeting and therapeutic efficacy. As a widely used commercialized antibody, rituximab has been in clinical use for three decades and has lengthened or even saved thousands of lives. However, many people cannot benefit from rituximab treatment because of drug resistance or side effects. Methods: In this study, a 13-nm rituximab-conjugated magnetic nanoparticle was developed as a therapeutic nanoprobe targeting CD20 overexpressing malignant lymphoma cells to enhance the treatment effects of rituximab. The magnetic cores (2,3-dimercaptosuccinicacid modified Fe3O4 nanoparticles, Fe3O4@DMSA) of the nanoprobes with an average diameter of 6.5 nm were synthesized using a co-precipitation method. Rituximab was then conjugated on the surface of Fe3O4@DMSA using a cross-linking agent (carbodiimide/N-hydroxysulfosuccinimide sodium salt). Based on theoretical calculations, approximately one antibody was coupled with one nanoparticle, excluding the multivalent antibody effect. Results: Cell targeting experiments and magnetic resonance (MR) signal and T2 measurements showed that the Fe3O4@DMSA@Ab nanoprobes have specific binding affinity for CD20-positive cells. Compared to rituximab and Fe3O4@DMSA, Fe3O4@DMSA@Ab nanoprobes significantly reduced cell viability and promoted Raji cell apoptosis. Initiating events of apoptosis, including increased intracellular calcium and reactive oxygen species, were observed in nanoprobe-treated Raji cells. Nanoprobe-treated Raji cells also showed the most drastic decrease in mitochondrial membrane potential and Bcl-2 expression, compared to rituximab and Fe3O4@DMSA-treated Raji cells. Conclusion: These results indicate that Fe3O4@DMSA@Ab nanoprobes have the potential to serve as MRI tracers and therapeutic agents for CD20-positive cells.

Detecting CD 20-Rituximab specific interactions on lymphoma cells using atomic force microscopy

Detecting CD 20-Rituximab interaction forces using AFM single-molecule force spectroscopy

Detecting CD20-Rituximab specific interactions on lymphoma cells using atomic force microscopy

Detecting CD20-Rituximab Interaction Forces Using AFM Single-Molecule Force Spectroscopy

Detecting the Micro/nano Physical Properties of Single Lymphoma Cells with Atomic Force Microscopy

AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells

[Distribution and Force Spectroscopy of CD20 Antigen-Antibody Binding on the B Cell Surface].

An experimental study on protein-protein interaction using atomic force microscopy

Measuring the molecular force of Burkitt's lymphoma patient cells using AFM

Imaging and measuring the protein distribution of lymphoma cells using atomic force microscopy.

Study on binding force by atomic force microscopy

Establishment of cluster of differentiation 20 immobilized cell membrane chromatography for the screening of active antitumor components in traditional Chinese medicine

An Easy Method to Detect the Kinetics of CD44 Antibody and Its Receptors on B16 Cells Using Atomic Force Microscopy

An Experimental Study on Imaging Burkitt's Lymphoma Cells by Atomic Force Microscope.

Rituxan Nanoconjugation Prolongs Drug/Cell Interaction and Enables Simultaneous Depletion and Enhanced Raman Detection of Lymphoma Cells

Decoding the molecular interplay of endogenous CD20 and Rituximab with fast volumetric nanoscopy

Sers Detection and Targeted Ablation of Lymphoma Cells Using Functionalized Ag Nanoparticles

Optical Tweezers and Raman Spectroscopy for Single-Cell Classification of Drug Resistance in Acute Lymphoblastic Leukemia.

Effect of a CrossMab cotargeting CD20 and HLA-DR in non-Hodgkin lymphoma

Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression

Eradication of Non-Hodgkin Lymphoma Through the Induction of Tumor-Specific T-cell Immunity by CD20-Flex BiFP.